### Title of Study: Sofosbuvir Plus Ribavirin Without Interferon For Treatment of Acute HCV in HIV-Infected Individuals (SWIFT-C)

#### Brief Description:
A5327/SWIFT-C is an open-label, two-cohort clinical trial, in which between 44 and 50 acutely HCV (any genotype including mixed genotype infection) infected HIV-1 positive subjects will be enrolled and administered oral SOF 400mg QD in combination with weight-based RBV (1000 or 1200 mg daily in two divided doses).

#### Inclusion/Exclusion Criteria:

**Inclusion:**
The study coordinator will review all of the criteria necessary to be eligible for the study. Listed below are a few key points.

- Documented HIV-1 infection and ≥ 18 years of age
- Presence of acute HCV infection within the last 6 months or recent re-infection of HCV
- Currently not on any antiretroviral therapy (ART) or on stable ART for at least 8 weeks prior to study entry. If you are on ART you will continue to take these during the study.
- Must agree to at least 2 reliable methods of birth control throughout the duration of the study. If you are pregnant or have a female partner that is current pregnant you will not be eligible to participate. Cannot have an active or acute AIDS-defining infection, other active, serious infections or a serious medical condition that would interfere with study participation

**Exclusion:**

- Prior exposure to a direct-acting antiviral (DAA) targeting the HCV NS5B polymerase.
  
  NOTE: DAAs include but are not limited to: mericitabine, ABT-333, ABT-072, BI-207127, BMS-791325, VX-222, tegobuvir, IDX719, sotrobuvir, GS-9669, VX-135.

- Chronic liver disease of a non-HCV etiology (eg, hemochromatosis, Wilson’s disease, α1 antitrypsin deficiency, cholangitis).

- Active, serious infection (other than HIV-1 or HCV) requiring parenteral antibiotics, antivirals, or antifungals

- Infection with hepatitis B virus (HBV) defined as HBsAg positive. Evidence of acute hepatitis A infection defined as HAV IGM positive

#### Treatment:
Study drugs will be sofosbuvir (SOF) and weight-based ribavirin (RBV) both taken by mouth. SOF will be taken every morning with food and the weight-based RBV will be taken twice a day (every morning and every night) with food. The treatment will last 8-12 weeks.

#### For more information contact:
Ericka R. Patrick, RN, MSN
404-616-6313
erpatri@emory.edu